Compare AVPT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVPT | HROW |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2008 |
| Metric | AVPT | HROW |
|---|---|---|
| Price | $13.02 | $33.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $16.64 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 1.4M | 487.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.00 | $31.62 |
| Revenue Next Year | $19.63 | $50.77 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.84 | $28.54 |
| 52 Week High | $15.58 | $54.98 |
| Indicator | AVPT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 35.19 |
| Support Level | $12.82 | $32.46 |
| Resistance Level | $13.91 | $36.37 |
| Average True Range (ATR) | 0.42 | 1.33 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 32.32 | 20.66 |
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.